All News
Filter News
Found 806,258 articles
-
Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct Offering
8/7/2019
The combined purchase price for one share of common stock and each warrant will be $0.75.
-
Glycomine, Inc. Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Disease of Glycosylation
8/7/2019
Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised $33 million in a Series B financing led by Novo Holdings A/S. Proceeds from the financing will be used to advance Glycomine's substrate replacement therapy for PMM2-CDG (CDG-1a
-
American College of Surgeons comments on the continual occurrence of firearm deaths and injuries in the United States
8/7/2019
Two mass shootings in less than 24 hours on August 3-4, 2019, have ravaged the communities of El Paso, Texas, and Dayton, Ohio, and devastated our entire nation. In response to these most recent tragedies, the American College of Surgeons (ACS) expresses its ongoing grave concern about the death and destruction that these violent incidents continually inflict on American life.
-
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
8/7/2019
Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine
-
Numerate Receives $2 Million SBIR Phase II Award to Continue Research Using Its AI-Driven Discovery Platform to Identify New Antiarrhythmic Drug
8/7/2019
Numerate and the UCLA Cardiovascular Research Laboratory to advance collaboration to identify superior therapy for treatment and prevention of ventricular tachycardias and fibrillation
-
Option Care and BioScrip Complete Merger to Form Option Care Health
8/7/2019
Option Care Enterprises, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) today announced the successful completion of their merger, which follows the satisfaction of the transaction’s closing conditions, including approval by BioScrip shareholders and the receipt of all necessary regulatory approvals.
-
Enhancing ROI by 17% for a Company in the Pharma Packaging Industry | Infiniti's Latest Success Story on Market Trend Analysis
8/7/2019
Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of their latest market trend analysis for a company in the pharma packaging industry.
-
Digital Health Company BlueDot Secures $7M USD Series A Financing
8/7/2019
The Co-operators and BDC Capital co-lead investment that will expand AI-driven infectious disease global early warning system
-
Leidos to Acquire IMX Medical Management Services
8/7/2019
Acquisition extends QTC's independent medical evaluation coverage area for commercial and federal customers
-
Inogen Announces Second Quarter 2019 Financial Results and Updates 2019 Guidance
8/7/2019
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended June 30, 2019.
-
Startups Qr8 Health and Enspire DBS Therapy Become Newest Tenants at Global Center for Health Innovation
8/7/2019
The Global Center for Health Innovation this month welcomed digital health startup Qr8 Health and medical device company Enspire DBS Therapy as its newest tenants, which will share a suite with an initial local staff of eight
-
TURALIO™ (pexidartinib), FDA Approved Treatment of TGCT, Available at Biologics by McKesson
8/7/2019
Exclusive distribution agreement with Daiichi Sankyo, Inc. expands rare disease and complex therapeutic specialty pharmacy needs
-
Exicure Appoints Dr. Bali Muralidhar of Abingworth LLP and Bosun Hau of Tybourne Capital Management to its Board of Directors
8/7/2019
Dr. Bali Muralidhar, a partner at Abingworth LLP, and Mr. Bosun Hau, a managing director and co-head of private equity at Tybourne Capital Management, to its Board of Directors.
-
Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
8/7/2019
Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, provides an update on the interim futility analysis of the PHOCUS study of Pexa-Vec in liver cancer.
-
Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D.
8/7/2019
Kronos Bio, Inc., a Two River portfolio company, today announced the appointment of Roger D. Kornberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Kornberg, a renowned biochemist, is Winzer Professor in Medicine in the Department of Structural Biology at Stanford University School of Medicine.
-
VIVA and Wiley Drive Open Access with Progressive New Agreement
8/7/2019
The two-year pilot utilizes the Wiley Open Access Account solution to allow VIVA researchers to publish in fully gold open access journals using a central fund for article publication charges
-
ArQule Reports Second Quarter 2019 Financial Results
8/7/2019
Conference call scheduled today at 9:00 a.m. ET
-
Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study
8/7/2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care will utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT™
-
Novanta to Present at the Baird Global Healthcare Conference on Wednesday, September 4, 2019
8/7/2019
Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chief Executive Office, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird Global Healthcare Conference on Wednesday, September 4, 2019, in New York, NY.
-
Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
8/7/2019
Phase 2 Personalized Cancer Vaccine (mRNA-4157) study initiated, with first patient consented